HPA axis activation determined by the CRH challenge test in patients with few versus multiple episodes of treatment-refractory depression

被引:28
作者
Ehnvall, A [1 ]
Sjögren, M
Zachrisson, OC
Ågren, H
机构
[1] Varberg Hosp, Res & Dev Unit, SE-43281 Varberg, Sweden
[2] Univ Gothenburg, Dept Psychiat, Inst Clin Neurosci, Gothenburg, Sweden
[3] Huddinge Univ Hosp, Div Psychiat, Neurotec Dept, Karolinska Inst, Stockholm, Sweden
关键词
life charting; treatment-refractory; depression; HPA axis; CRH stimulation test; ACTH;
D O I
10.1007/s00406-004-0512-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective in clinical guidelines, risk factors for a malignant illness course include 3 or more lifetime episodes of depression. Our aim was to investigate the activation of the hypothalamic-pituitary-adrenal hormonal axis in treatment-refractory affective disorder in pauciepisodic (one or two episodes) versus multi-episodic (three or more episodes) patients. Methods We evaluated the HPA axis in 37 patients with treatment-refractory affective disorder and in 27 healthy volunteers by measuring adrenocorticotropin hormone (ACTH) and cortisol responses following administration of corticotropin-releasing hormone (CRH). In retrospective life charts was recorded every previous illness episode for each patient. Results Seven of the patients were pauciepisodic and 30 were multiepisodic. The pauciepisodic patients had significantly larger peak and total ACTH responses to CRH compared to the multiepisodic patients as well as to the control group. Multiepisodic patients showed no difference compared to controls in ACTH secretion pre- and post-CRH. Cortisol secretion was the same in all three groups. Conclusions The pituitary adrenocortical responses were stronger in pauciepisodic patients than in multiepisodic patients and in volunteers. This cross-sectional study suggests that the HPA axis, in refractory multiepisodic affective disorders, might weaken its original activity as the illness recurs with more episodes.
引用
收藏
页码:349 / 355
页数:7
相关论文
共 40 条
[1]  
ASTONJONES G, 1994, CATECHOLAMINE FUNCTI, P17
[2]  
BANKI CM, 1987, AM J PSYCHIAT, V144, P873
[3]  
Bauer Michael, 2002, World J Biol Psychiatry, V3, P69, DOI 10.3109/15622970209150605
[4]   URINARY FREE CORTISOL EXCRETION IN DEPRESSION [J].
CARROLL, BJ ;
CURTIS, GC ;
DAVIES, BM ;
MENDELS, J ;
SUGERMAN, AA .
PSYCHOLOGICAL MEDICINE, 1976, 6 (01) :43-50
[5]  
CHAPPELL P B, 1986, Society for Neuroscience Abstracts, V12, P1443
[6]  
Cullinan William E., 1995, P3
[7]   Lifetime burden of mood swings and activation of brain norepinephrine turnover in patients with treatment-refractory depressive illness [J].
Ehnvall, A ;
Sjögren, M ;
Zachrisson, OCG ;
Agren, H .
JOURNAL OF AFFECTIVE DISORDERS, 2003, 74 (02) :185-189
[8]   Patterns of sensitisation in the course of affective illness -: A life-charting study of treatment-refractory depressed patients [J].
Ehnvall, A ;
Ågren, H .
JOURNAL OF AFFECTIVE DISORDERS, 2002, 70 (01) :67-75
[9]   BIOSYNTHESIS OF CORTICOTROPIN-RELEASING HORMONE IN HUMAN T-LYMPHOCYTES [J].
EKMAN, R ;
SERVENIUS, B ;
CASTRO, MG ;
LOWRY, PJ ;
CEDERLUND, AS ;
BERGMAN, O ;
SJOGREN, HO .
JOURNAL OF NEUROIMMUNOLOGY, 1993, 44 (01) :7-14
[10]  
ENDICOTT J, 1981, ARCH GEN PSYCHIAT, V38, P98